Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
GLUCOSE SODIUM CHLORIDE SODIUM LACTATE CALCIUM CHLORIDE DIHYDRATE MAGNESIUM CHLORIDE HEXAHYDRATE
Baxter Healthcare Limited
1.36 %w/v
Solution for Dialysis
1979-12-18
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dianeal PD1 Glucose 1.36% w/v 13.6 mg/ml Solution for Peritoneal Dialysis. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One litre of Peritoneal Dialysis Solution contains: This provides: For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for peritoneal dialysis. A clear, colourless, sterile aqueous solution, packed in PVC containers, each contained is a sealed plastic overpouch. The container may be fitted with an integral drainage/administration set. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dianeal PD1 is indicated whenever peritoneal dialysis is employed, including: 1. Acute and chronic renal failure. 2. Severe water retention. 3. Electrolyte Disorders. 4. Drug intoxication, when a more adequate therapeutic alternative is not available. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Administration_ DIANEAL PD1 is intended for intraperitoneal administration only. Not for intravenous administration. Peritoneal dialysis solutions may be warmed to 37°C to enhance patient comfort. However, only dry heat (for example, heating pad, warming plate) should be used. Solutions should not be heated in water due to an increased risk of contamination. Solutions should not be heated in a microwave oven due to the potential for damage to the container and patient injury or discomfort. Anhydrous Glucose 13.60 g which may be present as Glucose Monohydrate 15.00 g Sodium Chloride 5.67 g Sodium lactate 3.92 g Calcium Chloride Dihydrate 257.00 mg Magnesium Chloride Hexahydrate 152.00 mg Sodium 132.00 mmol Calcium 1.75 mmol Magnesium 0.75 mmol Chloride 102.00 mmol Lactate 35.00 mmol IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 08/02/2012_ _CRN 2 Read the complete document